Idiopathic Pulmonary Fibrosis News and Research

RSS
Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.
Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Study reveals beneficial anti-fibrotic effects of Pentraxin-2 in TGFβ1-induced lung disease

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

KineMed's fibrosis research program featured in Nature Medicine

KineMed's fibrosis research program featured in Nature Medicine

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

Today's opinions: Ariz. hospital and abortion; Wall Street Journal's issues with PolitiFact; Calif.'s anti-smoking success

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

Gilead stops ARTEMIS-IPF ambrisentan Phase III clinical trial in idiopathic pulmonary fibrosis

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

Gilead to acquire Arresto

Gilead to acquire Arresto

InterMune's MAA for Esbriet receives positive CHMP opinion

InterMune's MAA for Esbriet receives positive CHMP opinion

Stromedix obtains license from UCSF for integrin αvβ5 antibody

Stromedix obtains license from UCSF for integrin αvβ5 antibody

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

BIDMC, IPFnet to conduct clinical trials for idiopathic pulmonary fibrosis

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

Marker for aggressive form of idiopathic pulmonary fibrosis discovered

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Geron 2010 third quarter revenue increases from $494,000 to $546,000

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Amira initiates AM152 Phase 1 clinical study for fibrotic diseases

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

PFF’s national scientific conference improves clinical understanding of IPF

PFF’s national scientific conference improves clinical understanding of IPF

Roche receives development and commercialization rights for danoprevir drug

Roche receives development and commercialization rights for danoprevir drug

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

Volunteers, families in IL, IN, NY, and PA unite to raise money and awareness about pulmonary fibrosis

Amira submits IND application for AM152 antagonist

Amira submits IND application for AM152 antagonist

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.